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Summary
The scattering response of epithelial cells to activation of the
Met receptor tyrosine kinase represents one facet of an ‘‘inva-
sive growth’’ program [1, 2]. It is a complex event that incorpo-
rates loss of cell-cell adhesion, morphological changes, and
cell motility. Ubiquitination is a reversible posttranslational
modification that may target proteins for degradation or coor-
dinate signal transduction pathways [3, 4]. There are w79
active deubiquitinating enzymes (DUBs) predicted in the
human genome [5, 6]. Here, via a small interfering RNA
(siRNA) library approach, we have identified 12 DUBs that
are necessary for aspects of the hepatocyte growth factor
(HGF)-dependent scattering response of A549 cells. Different
phenotypes are evident that range from full loss of scattering,
similar to receptor knockdown (e.g., USP30, USP33, USP47),
to loss of cell-cell contacts even in the absence of HGF but
defective motility (e.g., USP3, ATXN3L). The knockdowns
do not incur defective receptor, phosphatidylinositol 3-
kinase, or MAP kinase activation. Our data suggest wide-
spread involvement of the ubiquitin system at multiple stages
of the Met activation response, implying significant crosstalk
with phosphorylation-based transduction pathways. Devel-
opment of small-molecule inhibitors of particular DUBs may
offer a therapeutic approach to contain metastasis.
Results and Discussion
We have grown lung adenocarcinoma A549 cells under condi-
tions where they form small islands typically consisting of 10–
25 cells. Upon stimulation with hepatocyte growth factor
(HGF), the cells scatter over a 12–16 hr time period to produce
a largely dispersed field of single motile cells, which we fix and
stain with crystal violet to enhance contrast for light micros-
copy. Alternatively, cells can be visualized by fluorescence
microscopy following DAPI staining. This process is inhibited
by knockdown of the Met receptor (Figure 1). We used these
assays to test for a role of deubiquitinating enzymes (DUBs)
in regulating the HGF scattering response. A549 cells were
depleted of specific DUBs with small interfering RNAs (siR-
NAs) for 85 human DUB genes (see Table S1 available online)
comprising a pool of four oligonucleotides targeting unique
sequences in each gene (siGenome library, Dharmacon).
Effects upon HGF-induced cell scattering were then observed
by light microscopy. Three repetitions of this screen were
examined by three observers each time and independently
scored for inhibition of scattering. This produced a consensus
list of 13 candidate DUBs (w15% of the total) drawn from 4 of
the 5 DUB families (no JAMM DUBs were identified).
*Correspondence: clague@liv.ac.ukTo assess the prevalence of off-target effects, we deconvo-
luted the oligonucleotide pools, which must contain at least
one inhibitory component, for each DUB candidate. If our
screen simply reflected nonspecific off-target inhibitory effects,
statistical considerations predict that only one or two of the 13
deconvoluted oligonucleotide pools would contain a second
inhibitory oligonucleotide. For 12 of the 13 targets, at least
two oligonucleotides effectively inhibited HGF-dependentscat-
tering. The exception, UCHL5, was not pursued further. In all, 35
of 52 oligos tested in these validation experiments produced
clearly discernible inhibitory effects (Table S2; Figure S1).
Within the group of 12 targets, we could observe different
phenotypic outcomes, which we separated broadly into three
classes (Figure 2): (1) large, flat cells (ATXN3L, UCHL1, USP3,
USP6, USP15, ZA20D1/Cezanne); (2) cells in which cell-cell
contacts had largely broken down but the cells remained clus-
tered (USP50, VCPIP1); and (3) cells remaining in tight clusters
similar to unstimulated or Met-depleted cells (USP1, USP30,
USP33, USP47). The class 1 phenotype was independent of
HGF stimulation (Figure 2) in all cases. We believe that this
reflects a general decrease in the motility of the cells, such
that they cannot move apart following HGF stimulation
although other aspects of the program may remain intact. In
the case of USP3 knockdown, cell-cell contacts were almost
completely lost prior to addition of HGF. Perhaps most inter-
esting is the class 3 phenotype, which is barely distinguishable
from knockdown of the Met receptor itself.
We examined the appearance of unstimulated cells
following each DUB knockdown with each of the individual oli-
gos from the initial pool. One interesting finding was that in
several instances, this led to a scattered phenotype (Table
S2; Figure S2), which is recessive in the context of the pool.
In all cases, the morphological appearance characteristic of
knockdown by pooled oligonucleotides was found with R2
individual oligonucleotides.
For some DUBs, we were able to judge the extent of knock-
down by using antibodies that recognize the endogenous
protein (UCHL1, USP1, USP15, USP33, USP47). With the
exception of USP1, there was a good correlation with knock-
down efficiency. A striking example is USP33, for which we
have now used a total of eight individual oligos, adding four
On-Target Plus oligos to the original four from the siGenome
pool. Figure 3A illustrates the knockdown efficiency of
USP33 and the strong correlation with scattering inhibition.
In the case of the mitochondrial DUB USP30 [7], we have vali-
dated that all four oligos, which inhibit scattering, effectively
suppress the expression of transfected USP30-GFP (Fig-
ure 3B) and endogenous mRNA levels (data not shown).
We next performed another assay reflecting cell invasion,
the wound-healing assay, which monitors the HGF-stimulated
migration of cells into a scratch made in a confluent monolayer
of A549 cells. Again, we observed that all DUBs identified
in our scattering screen, with the exception of USP3, also
inhibited this type of assay (Figure 4). Similar results were
obtained with the human pancreatic Panc1 cell line, the excep-
tions here being USP6 and USP47 (Figure S3).
The most trivial explanation of these results could be that
scattering inhibition might reflect defects in receptor
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ciated with cell scattering. We assayed total cellular Met
receptor levels following knockdown of each of the 12 DUBs
with the oligonucleotide pools. No major changes were
observed, with the exception of USP6, where receptor levels
declined by a factor of two (Figure S4A), but this effect could
largely be attributed to a single oligonucleotide (Figure S5).
The specific activity of Met receptor phosphorylation was as-
sayed by using a phospho-Met-specific antibody, and the
characteristic downregulation of receptor that follows acute
HGF stimulation was measured after 2 hr [8, 9]. In all cases,
the response appeared broadly normal (Figure S4B), indi-
cating that the receptor is initially at the cell surface, becomes
activated, and elicits the downstream response necessary for
lysosome-directed trafficking of activated receptor [9].
In Madin-Darby canine kidney cells, both MAP kinase and
phosphatidylinositol 3-kinase pathways are required for
HGF-induced adherens junction disassembly based on sensi-
tivity to pharmacological inhibitors [10]. We examined HGF-
dependent phosphorylation of a component of the MAP kinase
cascade, ERK, and of PKB/Akt, which is contingent upon
phosphatidylinositol 3-kinase activity [11] (Figures S6A and
S6B). In all cases, these major signaling pathways were largely
intact, with the exception of USP1, for which a 50% reduction
in phospho-ERK was observed (Figure S6A). However, this
effect of the pooled oligonucleotides did not deconvolute in
a manner that correlated with USP1 knockdown efficiency
and was not pursued (data not shown). An MTS assay
reflecting cell proliferation and viability also indicated no
significant effects following DUB knockdown (Figure S6C).
Focal adhesion kinase (FAK) is phosphorylated following
HGF treatment and stimulates the motility component of the
scattering response [12, 13]. No changes in HGF-induced
FAK phosphorylation were observed following knockdown of
each of the DUB targets, with the exception of USP6, but
again, this effect did not deconvolute to more than one indi-
vidual oligonucleotide (Figure S7).
Most of the DUBs we have identified in this screen are
poorly annotated. Notable exceptions are USP33, which is
known to interact with von Hippel-Lindau (VHL) protein [14];
ZA20D1/Cezanne, a negative regulator of the NFkB pathway
[15]; and USP1, which can deubiquitinate the DNA replication
processivity factor PCNA [16] and regulates the Fanconi
anemia pathway through deubiquitination of FANCD2 [17].
VCPIP1 interacts with p97, a highly abundant protein impli-
cated in a vast range of cellular activities including the
Figure 2. Morphological Features of A549 Cells following Selected DUB
Knockdown
Twelve deubiquitinating enzymes (DUBs) identified in our screen as
required for HGF-mediated scattering of A549 cells were knocked down
with pooled oligonucleotides from a siGenome library. One set of cells
was treated with 50 ng/ml HGF for 12 hr (+HGF panels), while the other
set was left untreated (2HGF panels). Cells were stained with crystal violet.
Scale bars represent 50 mm.
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Figure 1. Inhibition of HGF-Induced Scattering Response of A549 Cells by
siRNA Knockdown of the Met Receptor
(A) Reduction in cellular Met receptor levels following incubation with siRNA
oligos directed against the Met receptor.
(B) A549 cells treated with vehicle (Oligofectamine, left panels) or Met siRNA
(right panels) and stimulated with 50 ng/ml hepatocyte growth factor (HGF)
for 12 hr. Cells were fixed and stained with crystal violet (top panels) or DAPI
(bottom panels). Scale bars represent 100 mm.
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1465endoplasmic reticulum-associated degradation (ERAD)
pathway and HIF1a stability [18]. USP50 is likely to be a cata-
lytically inactive DUB [19]. Most pertinently, overexpression of
UCHL1 has been found to correlate with the metastatic pheno-
type of renal cell carcinomas [20], and USP6/TRE17 has been
suggested to be in complex with CDC42 and Rac1 regulating
actin rearrangements [21]. USP6 knockdown also leads to
decreased activation of Arf6, a GTPase associated with cell
invasion [22].
The screen reported here does not assess the requirements
for catalytic activity of the DUBs, but it seems reasonable to
assume that this will be the case in many instances. To date,
the major established role of ubiquitin following receptor tyro-
sine kinase stimulation has been to promote lysosomal degra-
dation of the receptor [23, 24]. Our data suggest hitherto unap-
preciated roles of ubiquitin-linked events in regulating the
outcomes of HGF signaling, although the relevant substrates
are currently unclear. The utility of DUBs as therapeutic drug
targets has been discussed, and some first-generation inhibi-
tors of USP7 and USP8 have recently been developed [25].
Several candidate DUBs arising from this screen suggest
themselves as novel targets for antimetastasis therapies.
Experimental Procedures
Oligonucleotides
A library of oligonucleotides targeting 85 DUBs was purchased from Dhar-
macon comprising pools of four individual oligonucleotides from their siGe-
nome collection. Individual oligonucleotides for deconvolution, as well as
four further oligonucleotides from their On-Target Plus collection in the
case of USP33, were also obtained from Dharmacon.
Antibodies
Antibodies were purchased from the following sources: mouse anti-Met
receptor, anti-phospho-Akt, and anti-phospho-MAPK from Cell Signaling;
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Figure 4. DUB Requirements for HGF-Dependent Wound Healing in A549
Cells
Confluent monolayers of A549 cells were pretreated for 72 hr with siRNA
oligonucleotides (40 nM) consisting of pools from the siGenome DUB library
targeting specific DUBs. After introducing a scratch, cells were incubated in
full medium supplemented with 50 ng/ml HGF and visualized 20 hr later.
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Figure 3. Correlation of USP33 and USP30 Knockdown Efficiency with
HGF-Induced Scattering Response in A549 Cells
(A) Estimation by western blotting of endogenous protein of the knockdown
efficiency for eight individual siRNA oligonucleotides directed against
USP33 (top) and their respective effects on HGF-mediated cell scattering
of A549 cells (bottom) (IS, inhibition of scattering; S, scattering).
(B) No antibody is currently available for USP30, but each of the four indi-
vidual oligonucleotides effectively represses transient expression of
USP30-GFP in HeLa cells as judged by western blotting with GFP-antibody,
as well as inhibiting HGF-mediated scattering of A549 cells (IS).
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1466rabbit anti-USP33, anti-USP15, and anti-USP47 from Bethyl Laboratories;
rabbit anti-UCHL1 from Abcam; and mouse anti-tubulin from Sigma. Rabbit
anti-USP1 was a gift from A. D’Andrea (Harvard University).
HGF-Dependent Cell Scattering Screen
A549 cells were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum and 1% nonessential amino acids.
Small islands of cells were seeded following limited trypsin digestion of
confluent cells and plated at 600 cells per well of a 48-well plate. Sixteen
hours later, siRNA oligonucleotides (40 nM) targeting specific DUBs were
delivered to cells with Oligofectamine. After 72 hr, cells were treated with
50 ng/ml HGF (gift of G. Vande Woude, Van Andel Research Institute, Grand
Rapids, MI) for 16 hr followed by fixation with paraformaldehyde. Cells were
then visualized by staining with crystal violet for bright-field microscopy or
DAPI for fluorescence microscopy.
Wound-Healing Assay
A549 cells were seeded in a 12-well plate at 28,000 cells per well. The
following day, they were transfected with library-derived pools of oligonu-
cleotides (40 nM) targeting specific DUBs with Oligofectamine. After 72 hr,
a linear scratch in the confluent cell monolayer was made with a sterile
pipette tip. Cells were rinsed and then incubated in full medium supple-
mented with HGF for 20 hr prior to fixation followed by staining with crystal
violet solution to enhance contrast. For each well, six pictures were taken at
103 magnification along the scratch area with a Leica DFC 350F phase-
contrast microscope.
Supplemental Data
Supplemental Data include seven figures and three tables and can be
found with this article online at http://www.cell.com/current-biology/
supplemental/S0960-9822(09)01466-3.
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